Janux Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Janux Therapeutics, Inc. (JANX) had Deferred Tax Assets, Operating Loss Carryforwards of $42.02 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $42.02M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $25.68M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $18.75M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $16.26M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $42.02M 10-K · filed 2026-02-26 |
| 2024-12-31 | $25.68M 10-K · filed 2026-02-26 |
| 2023-12-31 | $18.75M 10-K · filed 2025-02-27 |
| 2022-12-31 | $16.26M 10-K · filed 2024-03-08 |
| 2021-12-31 | $11.13M 10-K · filed 2023-03-10 |
| 2020-12-31 | $3.73M 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |